• 5 October 2019

    September’s top news stories

    NIH kick starts hunt for neuroprotective stroke treatments and Denali begins dosing Parkinson’s patients in Phase Ib trial. wraps up the key headlines from September 2019.

  • 5 September 2019

    August’s top news stories

    Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in...

  • 8 July 2019

    June’s top news stories

    AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).

  • 18 June 2019

    May’s top news stories

    Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The...

  • 3 May 2019

    April’s top news stories

    Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with...

  • 5 April 2019

    March’s top news stories

    Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients...

  • 5 March 2019

    February’s top news stories

    Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study...

  • 6 February 2019

    Sandoz Abandons US Development of Rixathon

    Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to have Rixathon approved in the US

  • 5 February 2019

    January’s top news stories

    Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic...


Go Top